There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Background & Aims Hepatocellular carcinoma (HCC) is the leading cause of death in
patients with chronic hepatitis. In this international collaboration, we sought to develop a …

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but
prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Hepatocellular carcinoma (HCC) usually arises in the context of a chronically damaged liver.
Liver functional estimation is of paramount importance in clinical decision making. The Child …

Background & Aims Previous prognostic scores for transarterial chemoembolization (TACE)
were mainly derived from real-world settings, which are beyond guideline …

Background IMbrave150 has established the superiority of atezolizumab plus bevacizumab
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …